{"id":"asp8477","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5095212","moleculeType":"Small molecule","molecularWeight":"325.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK9, ASP8477 aims to reduce the expression of oncogenic genes and induce apoptosis in cancer cells.","oneSentence":"ASP8477 is a small molecule that targets the CDK9 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:28.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT02065349","phase":"PHASE2","title":"A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-02-24","conditions":"Post-Herpetic Neuralgia (PHN), Neuropathic Pain, Painful Diabetic Peripheral Neuropathy (PDPN)","enrollment":132},{"nctId":"NCT02220777","phase":"PHASE1","title":"A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2010-11","conditions":"Pharmacokinetics of ASP8477, Pharmacodynamics of ASP8477","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASP8477","genericName":"ASP8477","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP8477 is a small molecule that targets the CDK9 protein. Used for Relapsed or refractory non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}